$SRRK

Gilman Michael sold $137K of SRRK

Gilman Michael sold 2,544 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.54–$54.81, $0.14M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gilman Michael
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include new company fundamentals such as guidance, trial results, contracts, or regulatory actions.

02

Market read

Primarily a sentiment/positioning datapoint for SRRK, with limited expected impact given the 10b5-1 structure.

03

What to watch

The article provides sale size and weighted prices but no context on total holdings, future planned sales, or whether other insiders have concurrent activity.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for trades dated 2026-07-01

Background

This is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp, reported as an open-market sale by a director under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Form 4 shows director Gilman Michael sold 2,544 SRRK shares in open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal, though it can add slight overhang sentiment if traders focus on insider selling.

Evidence & confidence

The transaction is disclosed via SEC Form 4 and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Traders may overreact to insider sales; 10b5-1 plans are often used to manage liquidity and taxes rather than signal bearish views.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider sale disclosure.

  • Gilman Michael

    Director who sold SRRK shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

$SRRKMed

Raymond James reiterates Scholar Rock stock rating on MAA resubmission

Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.

$SRRKMed

Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval

Scholar Rock (SRRK) resubmitted its European application for apitegromab, a treatment for spinal muscular atrophy (SMA), after addressing a manufacturing issue. The resubmission includes a new facility and is supported by Phase 3 trial results showing motor function improvements. The EMA is expected to issue an opinion in 2027. SRRK shares are currently trading at $41.48, down 1.71%.

$SRRKMed

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (SRRK) resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) for treating spinal muscular atrophy (SMA). The resubmission includes an alternate fill-finish facility, aligning with EMA guidance. The company anticipates a CHMP opinion in H1 2027. Apitegromab, marketed as ISEMBYLD in the U.S., is the first muscle-targeted therapy to show motor function improvement in SMA patients.